Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing growth for a drug that launched in 2022.
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback